Business steps in: Companies are also considering the potential for plasma.
Adam Schechter, CEO of testing firm LabCorp, told the Red Cross table that his company would offer free antibody testing through doctor’s offices to increase blood plasma donations. “LabCorp is currently working with public health authorities and the provider community on the details of the quarterly program and will provide additional information in the near future,” the company said in a statement.
Paul Perreault, CEO of CSL Limited, said his company and the NIH are designing a clinical trial to test a treatment known as hyperimmune globulin, which is derived from convulsive plasma. The company is registering patients in court next month. If it shows the treatment is effective, the CSL could file a claim with the FDA by the end of this year, Perreault said.
What to expect next: Hahn said the agency is reviewing data behind the effectiveness of conventional plasma. Clinical trials are ongoing and an urgent authorization from the FDA to extend plasma use may come soon.